Executive VP and President of Merck Research Laboratories
Dr. Peter S. Kim, Ph.D., is no longer Executive Vice President, President Merck Research Laboratories of Merck & Co., Inc., effective April 15, 2013. He is responsible for the Company?s research and development efforts worldwide. Since January 2008 ? Executive Vice President and President, Merck Research Laboratories, Merck & Co., Inc. ? responsible for the Company?s research and development efforts worldwide. Since January 2003 ? President, Merck Research Laboratories, Merck & Co., Inc. ? responsible for the Company?s research and development efforts worldwide.
The company has Return on Asset of 6.32 % which means that on every $100 spent on asset it made $6.32 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.21 % implying that it generated $11.21 on every 100 dollars invested.
The company has 20.57 B in debt with debt to equity (D/E) ratio of 0.37 which is OK given its current industry classification. Merck Co Inc has Current Ratio of 1.86 which is typical for the industry and considered as normal.
Merck & Co., Inc. offer various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care solutions worldwide. Merck Co Inc [MRK] is traded on New York Stock Exchange in USA. It is located in Whitehouse Station, NJ and employs 82,000 people. Filter other
Click "OK" to permanently delete this portfolio. Click "Cancel" if you have changed your mind.
Report was successfully generated.
You can either (1) right-mouth click the image to download it to your local drive or simply (2) copy and paste the
image data below to include picture of this graph on your web page without downloading the image file
Copy and paste above text right to your web page html
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide.
Please fill out our quick survey to help us provide your with a better service and user experience
Most of the functionality on our site is free to use.
However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented
capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory
NYSE Merck Co Inc
-0.16%
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
Hanover
Mexico
Paris
Buenos-Aires
